Literature DB >> 15711370

alpha1-Adrenergic mechanism in diabetic urethral dysfunction in rats.

Kazumasa Torimoto1, Yoshihiko Hirao, Hiroko Matsuyoshi, William C de Groat, Michael B Chancellor, Naoki Yoshimura.   

Abstract

PURPOSE: We investigated the contribution of alpha1-adrenoceptor mechanisms to urethral dysfunction associated with diabetes mellitus (DM) in rats.
MATERIALS AND METHODS: Eight weeks after streptozotocin injection (65 mg/kg intraperitoneally) the effects of DM on urethral relaxation mechanisms were evaluated with subjects under urethane anesthesia by simultaneous recordings of intravesical pressure in isovolumetric conditions and urethral perfusion pressure (UPP).
RESULTS: In diabetic rats the intravesical pressure thresholds for inducing urethral relaxation and the lowest urethral pressure (UPP nadir) during urethral relaxation were significantly higher by 142% and 86%, respectively, than in normal rats, while baseline UPPs were not significantly different. The mean rate of high frequency oscillations of urethral striated muscle in diabetic rats was also significantly lower by 23% than in normal rats. After alpha-bungarotoxin treatment (333 mug/kg intravenously) to eliminate striated muscle sphincter contractions the SD of baseline UPPs was significantly larger by 93% than in normal rats. Intravenous administration of terazosin (0.4 mg/kg), an alpha1-adrenoceptor antagonist, significantly decreased the UPP nadir, intravesical pressure thresholds inducing urethral relaxation and the SD by 41%, 87% and 138%, respectively, in diabetic rats but not in normal rats. In the 2 groups of animals after alpha-bungarotoxin treatment urethral relaxation during a reflex bladder contraction was inhibited by Nomega-nitro-L-arginine (40 mg/kg intravenously), a nitric oxide synthase inhibitor.
CONCLUSIONS: During reflex bladder contractions streptozotocin induced diabetic rats showed smooth and striated muscle dysfunctions of the urethra. The inhibition of alpha1-adrenoceptors, which decreased the UPP nadir and UPP fluctuation, may be useful for treating urethral dysfunction in DM.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15711370     DOI: 10.1097/01.ju.0000146268.45662.36

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  14 in total

1.  Grape seed proanthocyanidin extract alleviates urethral dysfunction in diabetic rats through modulating the NO-cGMP pathway.

Authors:  Bing Zhang; Zhaocun Zhang; Hong Ji; Hui Shi; Shouzhen Chen; Dongliang Yan; Xuewen Jiang; Benkang Shi
Journal:  Exp Ther Med       Date:  2017-11-13       Impact factor: 2.447

Review 2.  Pathophysiology and animal modeling of underactive bladder.

Authors:  Pradeep Tyagi; Phillip P Smith; George A Kuchel; William C de Groat; Lori A Birder; Christopher J Chermansky; Rosalyn M Adam; Vincent Tse; Michael B Chancellor; Naoki Yoshimura
Journal:  Int Urol Nephrol       Date:  2014-09-20       Impact factor: 2.370

Review 3.  Neural control of the lower urinary tract.

Authors:  William C de Groat; Derek Griffiths; Naoki Yoshimura
Journal:  Compr Physiol       Date:  2015-01       Impact factor: 9.090

4.  Concomitant alteration in number and affinity of P2X and muscarinic receptors are associated with bladder dysfunction in early stage of diabetic rats.

Authors:  Tsuyoshi Yoshizawa; Yukio Hayashi; Akira Yoshida; Shohei Yoshida; Yoshihiko Ito; Kenya Yamaguchi; Shizuo Yamada; Satoru Takahashi
Journal:  Int Urol Nephrol       Date:  2018-01-24       Impact factor: 2.370

5.  Urethral compensatory mechanisms to maintain urinary continence after pudendal nerve injury in female rats.

Authors:  Akira Furuta; Yasuyuki Suzuki; Koji Asano; William C de Groat; Shin Egawa; Naoki Yoshimura
Journal:  Int Urogynecol J       Date:  2011-03-29       Impact factor: 2.894

6.  Strain-dependent urethral response.

Authors:  Donna J Haworth; Takeya Kitta; Brian Morelli; Douglas W Chew; Naoki Yoshimura; William C de Groat; David A Vorp
Journal:  Neurourol Urodyn       Date:  2011-08-08       Impact factor: 2.696

7.  Therapeutic effects of a soluble guanylate cyclase activator, BAY 60-2770, on lower urinary tract dysfunction in mice with spinal cord injury.

Authors:  Daisuke Gotoh; Tetsuichi Saito; Sergei Karnup; Yosuke Morizawa; Shunta Hori; Yasushi Nakai; Makito Miyake; Kazumasa Torimoto; Kiyohide Fujimoto; Naoki Yoshimura
Journal:  Am J Physiol Renal Physiol       Date:  2022-08-11

8.  Differential vulnerabilities of urethral afferents in diabetes and discovery of a novel urethra-to-urethra reflex.

Authors:  Zhongguang Yang; Paul C Dolber; Matthew O Fraser
Journal:  Am J Physiol Renal Physiol       Date:  2009-10-28

9.  Functional and morphological alterations of the urinary bladder in type 2 diabetic FVB(db/db) mice.

Authors:  Liyang Wu; Xiaodong Zhang; Nan Xiao; Yexiang Huang; Michael Kavran; Rania A Elrashidy; Mingshuai Wang; Firouz Daneshgari; Guiming Liu
Journal:  J Diabetes Complications       Date:  2016-03-08       Impact factor: 2.852

Review 10.  Established and emerging treatments for diabetes-associated lower urinary tract dysfunction.

Authors:  Betül R Erdogan; Guiming Liu; Ebru Arioglu-Inan; Martin C Michel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2022-05-12       Impact factor: 3.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.